Bristol-Myers Squibb Company · NYSE:BMY

Bristol-Myers Squibb — UBS Healthcare Conference 2015

12 slides from Bristol-Myers Squibb's conference presentation, May 20, 2015

  1. Slide 1: UBS Healthcare Conference

    UBS Healthcare Conference Charlie Bancroft Executive Vice President, Chief Financial Officer May 20, 2015 NOT FOR PRODUCT PROMOTIONAL USE

  2. Slide 2: Forward-Looking Information

    Forward-Looking Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from

  3. Slide 3: Our Strategic Foundation

    Our Strategic Foundation Best of Best of BIOTECH PHARMA Diversified Specialty BioPharma I N N O VAT E I N T E G R AT E IMPROVE People helping patients in their fight against serious disease NOT FOR PRODUCT PROMOTIONAL USE 3

  4. Slide 4: Keys to Future Growth

    Keys to Future Growth Invest for long-term growth… balance short-term results Realize the potential of Immuno-Oncology Commercial execution of inline growth products Diversify for long-term sustainable growth Balanced approach to capital allocation NOT FOR PRODUCT PROMOTIONAL USE 4

  5. Slide 5: Q1 2015: Strong Sales Performance vs. Prior Year

    Q1 2015: Strong Sales Performance vs. Prior Year Q1 sales of $4B, up 6% vs. prior year $264 M >100 % 10 % 10 % 20 % $ 40 M NOT FOR PRODUCT PROMOTIONAL USE 5

  6. Slide 6: Our R&D Focus

    Our R&D Focus DISEASE AREA FOCUS Immuno- Oncology Immunoscience Cardiovascular Oncology Virology Fibrotic Genetically Diseases Defined Diseases Small Molecules Biologics Gene Therapy MODALITIES Millamolecules Antibody Drug Conjugates NOT FOR PRODUCT PROMOTIONAL USE 6

  7. Slide 7: ASCO 2015: Key I-O Data

    ASCO 2015: Key I-O Data • Results from Phase 3 Nivolumab studies – Squamous NSCLC (-017) – Non-squamous NSCLC (-057) – Mono Nivo and combo w/ Ipi in melanoma (-067) • Refractory multiple myeloma, elotuzumab (Eloquent 2) • Long term follow-up in renal cell carcinoma (-010) • New tumors: SCLC, Gliobla

  8. Slide 8: Capital Allocation: A Balanced Approach

    Capital Allocation: A Balanced Approach • Continue to be in a solid financial position – Strong balance sheet – Business development remains a top priority – Dividend commitment  6th consecutive annual increase NOT FOR PRODUCT PROMOTIONAL USE 8

  9. Slide 9: Business Development: Core to Our Strategy

    Business Development: Core to Our Strategy Licensing Acquisition Partnerships Strategically, Scientifically & Financially Aligned NOT FOR PRODUCT PROMOTIONAL USE 9

  10. Slide 10: Enhancing the Portfolio through Business Development

    Enhancing the Portfolio through Business Development Immuno-Oncology Oncology Specialty uniQure NOT FOR PRODUCT PROMOTIONAL USE 10

  11. Slide 11: Confident in Our Future

    Confident in Our Future Realizing the potential of I-O Strong performance from key product launches Diversified specialty pipeline to fuel growth Disciplined capital allocation Positioned for long-term success NOT FOR PRODUCT PROMOTIONAL USE 11 11

  12. Slide 12: UBS Healthcare Conference

    UBS Healthcare Conference Charlie Bancroft Executive Vice President, Chief Financial Officer May 20, 2015 NOT FOR PRODUCT PROMOTIONAL USE

Bristol-Myers Squibb Company — UBS Healthcare Conference 2015 on 6ix